Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics

András Perényi, György Bagdy, Mihály Arató, Ede Frecska

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neuroleptic treatment was instituted in 20 female schizophrenic patients, who had not received neuroleptics for at least the preceding 3 months. Both the therapeutic response to neuroleptics and the development of parkinsonian side effects were monitored in these patients. In addition, plasma dopamine-β-hydroxylase (DBH) and platelet monoamine oxidase (MAO) activities were measured. None of the neuroleptic responders developed parkinsonian symptoms. During the course of the 28-day treatment, there was a significant decrease in platelet MAO activity. There was a tendency for responders without parkinsonian symptoms to have lower plasma DBH activity than did nonresponders with parkinsonian symptoms.

Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalPsychiatry research
Volume13
Issue number2
DOIs
Publication statusPublished - Oct 1984
Externally publishedYes

Keywords

  • Neuroleptics
  • dopamine-β-hydroxylase
  • monoamine oxidase
  • therapeutic response neuroleptic-induced parkinsonism

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics'. Together they form a unique fingerprint.

  • Cite this